Methods and compositions for liquidation of tumors
AssigneeImmunovative Therapies Ltd.
InventorMichael Har-Noy
Life of this patent
Estimating the term…
Abstract
This invention relates to compositions and methods for immunotherapy of cancer. Specifically, a method of cancer immunotherapy is described which results in the systemic liquidation of both solid and metastatic tumors whereever they reside in the body. The compositions include activated allogeneic Th1 cells that when administered appropriately lead to liquidation of tumors. The method includes administering priming doses of the therapeutic composition, ablation of a selected tumor lesion along with intratumoral injection of the composition and then infusion of the therapeutic composition. These steps enable the systemic liquidation of tumors secondary to immune cell infiltration and leads to immune-mediated tumor eradication.
Claims17
A therapeutic composition comprising at least three components, the three components comprising:
- at least one foreign antigen;
- at least one Type I inflammatory cytokine;
- and
- at least one effector molecule capable of causing maturation of dendritic cells,
- wherein at least one of the three components is not produced by or expressed by the same source of living cells.
A therapeutic composition consisting essentially of three types of components:
- at least one foreign antigen;
- at least one Type I inflammatory cytokine;
- and
- at least one effector molecule capable of causing maturation of dendritic cells,
- wherein at least one of the three components is not produced by or expressed by the same source of living cells.
Dependencies are inferred from the claim text.